3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Multiple Myeloma
107
Precursor Cell Lymphoblastic Leukemia-Lymphoma
40
Recurrence
20
Leukemia
18
Burkitt Lymphoma
18
Lymphoma
17
Neoplasms, Plasma Cell
13
Lymphoma, Non-Hodgkin
13
Nausea
12
Lymphoma, Mantle-Cell
12
Vomiting
11
Waldenstrom Macroglobulinemia
10
Breast Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasms
9
Lymphoma, Follicular
9
Immunoglobulin Light-chain Amyloidosis
8
Lymphoma, B-Cell, Marginal Zone
7
Hodgkin Disease
7
Amyloidosis
7
Smoldering Multiple Myeloma
6
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Myeloid, Acute
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Prostatic Neoplasms
5
Leukemia, Biphenotypic, Acute
5
Hematologic Neoplasms
5
Sezary Syndrome
4
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Calcium Dobesilate
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts